Spikevax (Moderna mRNA-1273 COVID-19 vaccine) for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 prophylaxis (children) meta-analysis
teenCOVE (P203) (Adolescents 12-17Y) NCT04649151		RCT	Spikevax (Moderna mRNA-1273 COVID-19 vaccine)	placebo	COVID-19 prophylaxis (children)	some concern	2489/1243	suggested	suggested 93 % decrease in confirmed COVID (any severity) with a moderate degree of certainty due to some concern in risk of bias
1 study excluded by filtering options (1 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 prophylaxis (children) meta-analysis